Background: Despite targeted therapies impacted on progression-free survival in EGFR positive metastatic NoneSmall Cell lung carcinoma (NSCLC) these agents are not available in brazilian public health care system (SUS). Polychemotherapy based on platinum still being used in this situation in contrast with international guidelines. This analysis aims to estimate the impact of the lack of access to anti-EGFR therapies on the PFS of these patients. Method: The annual number of patients diagnosed with lung cancer was based on epidemiologic data of Cancer National Institute (INCA). Patients who have access to private health insurances were excluded. Only adenocarcinoma histology was considered. The INCA database, a cohort (Wong, 2016) and four clinical trials: EURTAC, LUX-Lung 3, LUX-Lung 7 and FLAURA were used to estimate stage distribution at diagnosis, recurrence rates and progression free survival in 2 years. The population without mutation in EGFR also was excluded. Results: INCA estimates 28,220 new cases of lung cancer per year in Brazil. Of these, 76.3% are supposed to treated in SUS, totalizing 21,532, upon which 3,790 (40%) have adenocarcinoma histology. Of these, 3,790 (44%) have metastasis at diagnosis, and 3,703 (43%), 603 (7%), 517 (6%) are diagnosed in stages III, II and I, respectively. A recurrences rate of 53.79% in stage III (1,992), 46.49% in II (280) and 26.06% in I (135) in 5 years from diagnosis. Of these, 28% have mutation in EGFR. The outcome of our study was that, if they were treated with polychemotherapy, only 71 would be free of progression after 24 months. In contrast, with the use of inhibitors of tyrosine kinase anti-EGFR, the expectation was 312 patients free from disease for Erlotinib, 377 for Gefitinib, 388 for Afatinib and 720 for Osimertinib. Conclusion: The monthly drug costs, in Brazil, were, approximately, R$ 4,000 for Gefitinib, R$ 5,000 for Afatinib, R$ 8,000 for Erlotinib and R$ 32,000 for Osimertinib. With this, a cost-effectiveness study, presented by Gilberto De Lima Lopes Jr. in ASCO this year, showed that Osimertinib, although its high PFS, was not cost-effective in our country. Larger discounts, pharmaceutics support and more clinical trials are necessary to improve access to Osimertinib. In contrast, the incorporation of Gefitinib, Afatinib and Erlotinib in the public health care system should influence in PFS. Despite this, our study showed that, in two years, should avoid the progression of disease in 378 patients. Background: Approximately 10e12% of patients with EGFRm+ NSCLC have tumors harboring uncommon EGFR mutations; however, there is a paucity of clinical data on the sensitivity of these tumors to EGFR tyrosine kinase inhibitors (TKIs). The clinical activity of afatinib, an irreversible ErbB family blocker, has been assessed in patients with NSCLC harboring certain uncommon EGFR mutations. Method: Here, we review the key clinical data available for afatinib in EGFRm+ NSCLC harboring uncommon EGFR mutations. Results: Post-hoc analysis of the Phase II LUX-Lung 2, and Phase III randomized LUX-Lung 3, and 6, trials 1 identified 75 afatinib-treated pts with NSCLC harboring
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Classification of Lung Tumors, we investigated whether lung tumor histology serves as a clinical factor that predicts short-term and longterm perioperative outcomes. Method: We retrospectively analyzed patients who underwent robotic-assisted video-thoracoscopic lobectomy by one surgeon over 81 months. Patients were grouped by tumor histology based on final pathology report. Patients' demographics, smoking history, lobar tumor location, extent of resection, intraoperative outcomes, perioperative complications, and hospital length of stay (LOS) were compared. Results: Among 420 study patients, the most common tumor type was adenocarcinoma (AD, 59.8%), followed by squamous cell carcinoma (SQ, 19.3%) and neuroendocrine carcinoma (NEC, 11.7%). Final histology for the remainder of the study cohort consisted of adenosquamous carcinoma (AdSq, 2.1%) and pulmonary metastasis (PM, 7.1%). All patients with AdSq histology had a positive smoking history, while those with NEC histology had the lowest smoking history rate (100% vs 71.4%; p<0.001). Patients with AdSq histology were both older and had larger tumors at time of resection (p<0.001 and p¼0.003, respectively). Patients with AdSq histology required more extensive resections (p<0.004) and experienced greater estimated blood loss (EBL; p¼0.005) and longer operative times (p¼0.018) than the other three groups. While SQ or PM patients had slightly more postoperative complications, this difference was not significant (p¼0.990). Patients with AdSq and PM histology had significantly worse 3-year overall survival (3-yr OS) (20.0% and 52.4%, respectively) compared to 76.2% and 73.9% for AD and NEC patients, respectively (p0.001). Conclusion: Patients with AdSq histology were older and had larger tumors, which put them at risk of intraoperative difficulties, with more extensive resections, longer operative times, and greater EBL. Having AdSq histology did not affect the short-term postoperative course, but AdSq histology resulted in worse 3-yr OS. Keywords: lung, tumor histology, prognostic factor, postoperative outcomes
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